Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 65,845 shares, a drop of 56.7% from the October 15th total of 151,925 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 143,495 shares, the short-interest ratio is currently 0.5 days.
Analysts Set New Price Targets
Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.
View Our Latest Stock Report on Astellas Pharma
Astellas Pharma Price Performance
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06). The company had revenue of $3.98 billion during the quarter, compared to analyst estimates of $3.79 billion. Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. As a group, analysts anticipate that Astellas Pharma will post 1.40 EPS for the current year.
About Astellas Pharma
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
Featured Articles
- Five stocks we like better than Astellas Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
